Avidity Biosciences (RNA) Q4 2024 earnings summary

Executive summary

• Achieved successful readouts from three clinical-stage programs in 2024, reinforcing the AOC platform's consistency and reproducibility.

• Completed enrollment in the EXPLORE44-OLE study, supporting a planned BLA submission for del-zota by year-end 2025.

• Commercial preparations are underway for three potential product launches (DMD, DM1, FSHD) starting in 2026.

• Expanded pipeline into precision cardiology and next-generation technology innovations.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled approximately $1.5 billion as of December 31, 2024.

• Collaboration revenue was $3.0 million for Q4 2024 and $10.9 million for the full year, primarily from partnerships with Bristol Myers Squibb.

• R&D expenses were $95.6 million for Q4 2024 (up from $52.8 million in Q4 2023) and $303.6 million for the year (up from $191.0 million in 2023), driven by clinical program advancements.

• G&A expenses were $28.3 million for Q4 2024 (up from $16.1 million in Q4 2023) and $86.2 million for the year (up from $54.2 million in 2023), reflecting increased personnel costs.

• Net loss was $102.3 million for Q4 2024 and $322.3 million for the year, compared to $60.4 million and $212.2 million, respectively, in 2023.

Outlook and guidance

• Anticipates major milestones for each rare neuromuscular program in 2025, including BLA submission for del-zota and potential global Phase 3 trial initiation for del-brax.

• Plans for three potential successive product launches starting in 2026.

• Ongoing commercial infrastructure development supported by a strong balance sheet.